These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 38579326)

  • 1. Cannabinoids and Postcardiac Surgery: Preclinical Insights Pave the Way for Future Research.
    Martinez Naya N; Denicolai M; Kelly J; Toldo S
    J Cardiovasc Pharmacol; 2024 Jun; 83(6):531-533. PubMed ID: 38579326
    [No Abstract]   [Full Text] [Related]  

  • 2. Cannabinoids and multiple sclerosis.
    Pertwee RG
    Mol Neurobiol; 2007 Aug; 36(1):45-59. PubMed ID: 17952649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Research progress on anti-inflammatory effects of plant-derived cannabinoid type 2 receptor modulators].
    Lian CX; Hu SJ; Zhang QY; Zhao QM; Qin LP; Gong W
    Zhongguo Zhong Yao Za Zhi; 2023 Dec; 48(23):6294-6306. PubMed ID: 38211986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic opportunities through modulation of the endocannabinoid system.
    Makriyannis A; Mechoulam R; Piomelli D
    Neuropharmacology; 2005 Jun; 48(8):1068-71. PubMed ID: 15885714
    [No Abstract]   [Full Text] [Related]  

  • 5. The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55.
    Sharir H; Console-Bram L; Mundy C; Popoff SN; Kapur A; Abood ME
    J Neuroimmune Pharmacol; 2012 Dec; 7(4):856-65. PubMed ID: 22454039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The therapeutic potential of novel cannabinoid receptors.
    Kreitzer FR; Stella N
    Pharmacol Ther; 2009 May; 122(2):83-96. PubMed ID: 19248809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects.
    Hu SJ; Cheng G; Zhou H; Zhang Q; Zhang QL; Wang Y; Shen Y; Lian CX; Ma XQ; Zhang QY; Qin LP
    Molecules; 2022 Jan; 27(3):. PubMed ID: 35163968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabinoids for the treatment of behavioral and psychological symptoms of dementia.
    Tampi RR; Young JJ; Tampi DJ
    Neurodegener Dis Manag; 2018 Aug; 8(4):211-213. PubMed ID: 30040030
    [No Abstract]   [Full Text] [Related]  

  • 9. Cannabimimetic plants: are they new cannabinoidergic modulators?
    Kumar A; Premoli M; Aria F; Bonini SA; Maccarinelli G; Gianoncelli A; Memo M; Mastinu A
    Planta; 2019 Jun; 249(6):1681-1694. PubMed ID: 30877436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect sympatholytic actions at β-adrenoceptors account for the ocular hypotensive actions of cannabinoid receptor agonists.
    Hudson BD; Beazley M; Szczesniak AM; Straiker A; Kelly ME
    J Pharmacol Exp Ther; 2011 Dec; 339(3):757-67. PubMed ID: 21885619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neuropharmacology of cannabinoid receptor ligands in central signaling pathways.
    Brunt TM; Bossong MG
    Eur J Neurosci; 2022 Feb; 55(4):909-921. PubMed ID: 32974975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings.
    Lötsch J; Weyer-Menkhoff I; Tegeder I
    Eur J Pain; 2018 Mar; 22(3):471-484. PubMed ID: 29160600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The molecular basis for neuroimmune receptor signaling.
    Rogers TJ
    J Neuroimmune Pharmacol; 2012 Dec; 7(4):722-4. PubMed ID: 22935971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the endocannabinoid system: future therapeutic strategies.
    Aizpurua-Olaizola O; Elezgarai I; Rico-Barrio I; Zarandona I; Etxebarria N; Usobiaga A
    Drug Discov Today; 2017 Jan; 22(1):105-110. PubMed ID: 27554802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence.
    Scuteri D; Rombolà L; Hamamura K; Sakurada T; Watanabe C; Sakurada S; Guida F; Boccella S; Maione S; Gallo Afflitto G; Nucci C; Tonin P; Bagetta G; Corasaniti MT
    Biomed Pharmacother; 2022 Feb; 146():112505. PubMed ID: 34891121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.
    Davis MP
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1123-40. PubMed ID: 24836296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective.
    Cooper ZD; Craft RM
    Neuropsychopharmacology; 2018 Jan; 43(1):34-51. PubMed ID: 28811670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoids, endocannabinoids, and cancer.
    Hermanson DJ; Marnett LJ
    Cancer Metastasis Rev; 2011 Dec; 30(3-4):599-612. PubMed ID: 22038019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocannabinoids, cannabinoids and the regulation of anxiety.
    Petrie GN; Nastase AS; Aukema RJ; Hill MN
    Neuropharmacology; 2021 Sep; 195():108626. PubMed ID: 34116110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoids against pain. Efficacy and strategies to reduce psychoactivity: a clinical perspective.
    Karst M; Wippermann S
    Expert Opin Investig Drugs; 2009 Feb; 18(2):125-33. PubMed ID: 19236260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.